BioCardia, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 07:33 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $69.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $115.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $0 | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $0 | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $2.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $4.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-04-01 to 2021-06-30 | $1.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2021-01-01 to 2021-06-30 | $2.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$3.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$6.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$3.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$6.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | −$0.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | −$0.38 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $55.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $18.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $19.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $20.2m | us-gaap:Assets |
| Total liabilities | At period end2021-06-30 | $4.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $15.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-21-019540. Last ingested by Listed: Nov 6, 2026, 12:20 ET. Listed shows no prices and gives no investment advice.